Functional coronary angiography significantly reduced cardiovascular events and improved safety compared with conventional ...
The U.S. Food and Drug Administration (FDA) has approved daraxonrasib for patients whose pancreatic cancer has spread to ...
A registry-based digital strategy that identified untreated patients and invited them to a telephone consultation more than ...
Monotherapy using prasugrel failed to show noninferiority compared with potent antiplatelet therapy plus aspirin at the time ...
Milvexian did not reduce major adverse cardiovascular events compared with placebo after a recent acute coronary syndrome and ...
Prasugrel reduced major cardiovascular events to the same extent as ticagrelor but with lower major bleeding after coronary ...
Antiplatelet monotherapy reduced bleeding but dual therapy provided greater cardiovascular event protection in patients at ...
Potent antiplatelet therapy increased bleeding without signs of benefit regarding cardiovascular events in patients with ...
Atorvastatin reduced major cardiovascular events by 30% in older people without known cardiovascular disease, diabetes or ...
The investigational anti-interleukin-6 (IL-6) monoclonal antibody pacibekitug produced sustained reductions in ...
Edoxaban did not reduce stroke or systemic embolism but increased major bleeding in high-risk patients with atrial ...
Immediate initiation of evolocumab after a heart attack significantly improved low-density lipoprotein cholesterol (LDL-C) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results